The retrospective study, conducted at the Thomas Jefferson University in Philadelphia, found that watchful waiting among black men with early stage prostate cancer who had undergone surgery, resulted in a more aggressive disease.
Monitoring early stage prostate cancer instead of treating it may not be appropriate for all patients, especially black men, a new study indicates.
According to background information with the study, there is currently controversy among oncologists over the best way to handle early stage prostate cancer, with some experts suggesting that regular monitoring -- known as watchful waiting -- of the disease is the best approach because it avoids overtreatment.
But this new study suggests that watchful waiting may not be suitable for all men with early stage prostate cancer, especially black patients.
"We know that African-American men have more aggressive prostate cancer than Caucasian men," Dr. Kosj Yamoah, chief resident in the department of radiation oncology at Thomas Jefferson University in Philadelphia, said in a university news release.
Read the complete press release: http://bit.ly/1sdIIyc
Source: US News
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More